14 research outputs found
Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension
Bone and mineral researc
Evaluation of Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab: Results From the Pivotal Phase 3 Fracture Study Extension
Bone and mineral researc
Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years
Bone and mineral researc
Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years
relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment
Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment
TEN YEARS OF DENOSUMAB (DMAB) TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM EXTENSION TRIAL
Bone and mineral researc
Extended Safety Observations From Denosumab Administration in Postmenopausal Women From the FREEDOM and FREEDOM Extension Trials
Endocrinolog
6 years' Denosumab treatment in postmenopausal women with osteoporosis: first 3 years of the FREEDOM Extension
6 YEARS' DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: FIRST 3 YEARS OF THE FREEDOM EXTENSION
Bone and mineral researc